Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer

Conclusions Our findings suggest that MS4A12 and CDX2 gene polymorphisms may predict outcome in stage III CRC. However, the clinical significance of SNPs for response to oxaliplatin may differ by tumor stage.
Source: Pharmacogenetics and Genomics - Category: Genetics & Stem Cells Tags: Original Articles Source Type: research